Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus sintilimab and chemotherapy versus sintilimab plus chemotherapy in first-line advanced squamous NSCLC
ChiCTR2300076928Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab, carboplatin and paclitaxel in Pulmonary squamous cell carcinoma (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Objective response rate and Correlation of oral microbiome with efficacy. Started Mar 2024; status: recruiting.
02
Drugs
sintilimabcarboplatinpaclitaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2300076928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076928.